MBX Quote, Financials, Valuation and Earnings

Ionis Pharmaceuticals, Inc. has a net margin of -- compared to MBX Biosciences, Inc.'s net margin of -82.06%. MBX Biosciences, Inc.'s return on equity of -29.36% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

MBX Biosciences, Inc. has a consensus price target of $58.63, signalling upside risk potential of 83.38%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $85.47 which suggests that it could grow by 4.64%. Given that MBX Biosciences, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe MBX Biosciences, Inc. is more attractive than Ionis Pharmaceuticals, Inc..

MBX Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.45%.

MBX Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MBX Biosciences, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

MBX Biosciences, Inc. quarterly revenues are --, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. MBX Biosciences, Inc.'s net income of -$21.6M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, MBX Biosciences, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MBX Biosciences, Inc. is -- versus 13.91x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -- compared to MBX Biosciences, Inc.'s net margin of 21.47%. MBX Biosciences, Inc.'s return on equity of -29.36% beat Johnson & Johnson's return on equity of 33.27%.

MBX Biosciences, Inc. has a consensus price target of $58.63, signalling upside risk potential of 83.38%. On the other hand Johnson & Johnson has an analysts' consensus of $203.42 which suggests that it could grow by 0.74%. Given that MBX Biosciences, Inc. has higher upside potential than Johnson & Johnson, analysts believe MBX Biosciences, Inc. is more attractive than Johnson & Johnson.

MBX Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.

MBX Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.55% to investors and pays a quarterly dividend of $1.30 per share. MBX Biosciences, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

MBX Biosciences, Inc. quarterly revenues are --, which are smaller than Johnson & Johnson quarterly revenues of $24B. MBX Biosciences, Inc.'s net income of -$21.6M is lower than Johnson & Johnson's net income of $5.2B. Notably, MBX Biosciences, Inc.'s price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 19.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MBX Biosciences, Inc. is -- versus 5.31x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals, Inc. has a net margin of -- compared to MBX Biosciences, Inc.'s net margin of -39.75%. MBX Biosciences, Inc.'s return on equity of -29.36% beat Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56%.

MBX Biosciences, Inc. has a consensus price target of $58.63, signalling upside risk potential of 83.38%. On the other hand Madrigal Pharmaceuticals, Inc. has an analysts' consensus of $563.80 which suggests that it could fall by -2.34%. Given that MBX Biosciences, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe MBX Biosciences, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..

MBX Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals, Inc. has a beta of -1.034, suggesting its less volatile than the S&P 500 by 203.399%.

MBX Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MBX Biosciences, Inc. pays -- of its earnings as a dividend. Madrigal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

MBX Biosciences, Inc. quarterly revenues are --, which are smaller than Madrigal Pharmaceuticals, Inc. quarterly revenues of $287.3M. MBX Biosciences, Inc.'s net income of -$21.6M is higher than Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M. Notably, MBX Biosciences, Inc.'s price-to-earnings ratio is -- while Madrigal Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MBX Biosciences, Inc. is -- versus 17.29x for Madrigal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -- compared to MBX Biosciences, Inc.'s net margin of 33.68%. MBX Biosciences, Inc.'s return on equity of -29.36% beat Merck & Co., Inc.'s return on equity of 39.63%.

MBX Biosciences, Inc. has a consensus price target of $58.63, signalling upside risk potential of 83.38%. On the other hand Merck & Co., Inc. has an analysts' consensus of $106.62 which suggests that it could grow by 6.92%. Given that MBX Biosciences, Inc. has higher upside potential than Merck & Co., Inc., analysts believe MBX Biosciences, Inc. is more attractive than Merck & Co., Inc..

MBX Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

MBX Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.25% to investors and pays a quarterly dividend of $0.81 per share. MBX Biosciences, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

MBX Biosciences, Inc. quarterly revenues are --, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. MBX Biosciences, Inc.'s net income of -$21.6M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, MBX Biosciences, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 13.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MBX Biosciences, Inc. is -- versus 3.93x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.